SGLT-2 Inhibitors in Chronic Kidney Disease
NCL ICB are commissioning a program of work from January 2025 to March 2026, to review patients with CKD stages G3a-G5 who could be prescribed an SGLT2 inhibitor, but who are not currently prescribed the medication. This intervention will be beneficial to the patient’s health and self-management of their condition.
SGLT-2i used appropriately in CKD can impact significantly on both the rates of heart attacks and strokes in these patients, but also to reduce the number who reach end stage kidney disease and renal replacement therapy.
To support this work, please join a one hour interactive session with experts from the NCL Chronic Kidney Disease Integrated Service.
Learn:
What are the benefits to prescribing an SGLT-2 inhibitor in CKD when appropriate - for both patients and the wider healthcare system?
How have suitable patients been identified through searches? Who should we focus on?
What are the updated NCL CKD Pathway (launched January 2025) recommendations for using SGLT-2i in CKD?
All sessions are 1-2pm
Wednesday February 12th: book here
Thursday February 27th: book here
Friday March 7th: book here
Tuesday March 11th: book here
Tuesday 1st April: book here
Wednesday 2nd April: book here
Friday 25th April: book here
Any questions, contact: rf.communityckdservice@nhs.net.